Rosetta Genomics (ROSG) Tops Q2 EPS by 2c

Rosetta Genomics (NASDAQ: ROSG) reported Q2 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $3.01 million.

For earnings history and earnings-related data on Rosetta Genomics (ROSG) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Aon names interim CFO as Edmund Reese exits the firm